[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-myeloid-leukemia---accelerated-phase\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-myeloid-leukemia---accelerated-phase":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100577747","phase-2-intensity-modulated-total-marrow-irradiation-in-fully-human-leukocyte-antigen-hla-matched-and-partially-hla-mismatched-allogeneic-transplantation-patients-with-high-risk-acute-myeloid-leukemia-aml-chronic-myeloid-leukemia-cml-and-myelodysplastic-syndrome-mds-100577747",false,"NCT06802315","Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)","A Phase II Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Myeloablative Fludarabine\u002FBusulfan and Post-Transplant Cyclophosphamide (PTCY) for Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk AML, CML, and MDS","BMT-13","Inclusion Criteria:\n\n* 1\\. Age 18-65 years.\n* 2\\. Patients with CML, AML, or MDS who meet one of the following criteria: 2a. Relapsed or refractory AML (including AML in CR2) 2b. Poor-risk AML in first remission, with remission defined as \\\u003C5% bone marrow blasts morphologically:\n* AML arising from MDS, a myeloproliferative disorder, or secondary AML\n* Poor risk molecular features according to Leukemia Net including ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and\u002For ZRSR2\n* Poor-risk cytogenetics: Monosomal karyotype, complex karyotype (\\> 3 abnormalities), inv (3), t(3;3), t(6;9), MLL rearrangement with the exception of t(9;11), or abnormalities of chromosome 5 or 7. 2c. Primary refractory disease 2d. MDS with at least one of the following poor-risk features:\n* Poor-risk cytogenetics including 3q abnormalities, 7\u002F7q minus or complex cytogenetics (\\>3 abnormalities).\n* Current or previous INT-2 or high IPSS score.\n* Treatment-related MDS.\n* MDS diagnosed before the age of 21 years.\n* Progression on or lack of response to standard DNA-methyltransferase inhibitor therapy.\n* Life-threatening cytopenias, including those requiring regular PRBC or platelet transfusions. 2e. CML with a history of accelerated or blast phase.\n\nExclusion Criteria:\n\n* 1\\. Presence of significant co-morbidity as shown by:\n* 1a. Left ventricular ejection fraction \\\u003C 50%\n* 2b. Creatinine clearance \\\u003C30ml\u002Fmin.\n* 3c. Bilirubin \\> 2.0 mg\u002FdL (unless due to Gilbert's syndrome or hemolysis), and ALT and AST \\> 5 x ULN.\n* 4d. FEV1 and FVC \\\u003C 50% of predicted or DLCO \\\u003C50% of predicted once corrected for anemia.\n* 5e. Karnofsky score \\\u003C70\n* 6f. Active viral hepatitis or HIV infection.\n* 7g. Cirrhosis.\n* 2\\. Pregnancy or breast feeding\n* 3\\. Patients unable to sign informed consent.\n* 4\\. Patients previously received radiation to \\>20% of bone marrow-containing areas.","ALL","18 Years","65 Years",{"count":21,"type":22},38,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The study is a Phase II clinical trial. Patients will receive intensity-modulated total marrow irradiation (TMI) at a dose of 9 Gray (Gy) with standard myeloablative fludarabine intravenous (IV) and targeted busulfan (FluBu4) conditioning prior to allogeneic hematopoietic stem cell transplant (HSCT). Graft-versus-host disease (GVHD) prophylaxis will include Cyclophosphamide on Day +3 and +4, tacrolimus, and mycophenolate mofetil.",[28,29,30,31],"Acute Myeloid Leukemia, Relapsed, Adult","Acute Myeloid Leukemia Refractory","Chronic Myeloid Leukemia - Accelerated Phase","Myelodysplastic Syndromes",[33,34,35],"Total Marrow Irradiation","Stem Cell Transplant","Allogenic Transplant","RECRUITING","2026-06-23",{"date":39,"type":40},"2026-06-26","ACTUAL",{"date":42,"type":40},"2025-02-04",{"date":44,"type":22},"2032-03",{"name":46,"class":47},"University of Illinois at Chicago","OTHER"]